Beta-2 Glycoprotein I Ab, IgA
Anti-β2 Glycoprotein 1
Beta-2 Glycoprotein 1 Antibodies
Assess the risk of thrombosis in patients who may be at risk for antiphospholipid syndrome (APS). This test should be used in conjunction with current traditional anticardiolipin and anticoagulant tests.
Anti-β2-glycoprotein 1 should not be used alone as a screening test for antiphospholipid syndrome. A common aspect to all assays for anticardiolipin antibodies (ACA) is the requirement that the assay system include a source of plasma proteins. It has been determined that, in many patients, β2-glycoprotein 1 (β2-GP1) is the plasma factor required for ACA binding. Solid-phase enzyme immunoassays that detect antibodies that bind to β2-GP1 in the absence of phospholipid are now part of the diagnostic arsenal for APS. β2-GP1-dependent binding is frequently detected in patients with clinical symptoms of APS. All three isotypes of anti-β2-GP1 (IgG, IgM, and IgA) have been associated with thrombosis. ACA that do not require β2-GP1 are usually transient and not clinically significant. Studies have shown that ACA associated with infections tend to not be β2-GP1-dependent. This supports the conclusion that anti-β2-GP1 assays may be more specific for APS than ACA. While the majority of patients with LA will also test positive for ACA and β2-GP1 antibodies, approximately 30% of patients tested will have discordant results. Approximately 20% of patients who test negative for ACA will test positive for β2-GP1.8 Anti-β2-GP1 testing can be useful in the evaluation of patients with positive ACA results and a clinical picture that is not consistent with APS. A negative anti-β2-GP1 result in this context would not support a diagnosis of APS. Anti-β2-GP1 testing can also support the diagnosis of APS in patients with a strong clinical picture for APS with negative LA and ACA results.
Red-top tube or gel-barrier tube